Sientra Inc (NASDAQ:SIEN) CFO Paul Sean Little bought 17,391 shares of Sientra stock in a transaction dated Friday, June 7th. The shares were acquired at an average cost of $5.75 per share, for a total transaction of $99,998.25. Following the completion of the purchase, the chief financial officer now directly owns 94,891 shares of the company’s stock, valued at approximately $545,623.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ SIEN opened at $6.44 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.16 and a current ratio of 1.52. Sientra Inc has a twelve month low of $5.00 and a twelve month high of $26.79. The company has a market cap of $186.98 million, a P/E ratio of -1.98 and a beta of 0.26.
Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.15). Sientra had a negative net margin of 126.32% and a negative return on equity of 119.59%. The firm had revenue of $17.55 million for the quarter, compared to the consensus estimate of $17.00 million. Research analysts predict that Sientra Inc will post -2.81 EPS for the current fiscal year.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Sientra from a “sell” rating to a “hold” rating in a research note on Wednesday, April 17th. BidaskClub raised Sientra from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 25th. Craig Hallum set a $23.00 price target on Sientra and gave the company a “buy” rating in a research report on Monday, April 22nd. William Blair lowered Sientra from an “outperform” rating to a “market perform” rating in a research report on Wednesday, March 13th. Finally, Wells Fargo & Co upgraded Sientra from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $8.00 to $10.00 in a research report on Wednesday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $21.13.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. boosted its position in shares of Sientra by 101.7% in the 4th quarter. Citigroup Inc. now owns 19,000 shares of the medical instruments supplier’s stock worth $241,000 after purchasing an additional 9,579 shares in the last quarter. Tarbox Family Office Inc. boosted its position in shares of Sientra by 273.9% in the 1st quarter. Tarbox Family Office Inc. now owns 36,400 shares of the medical instruments supplier’s stock worth $312,000 after purchasing an additional 26,666 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Sientra in the 4th quarter worth $29,000. Great West Life Assurance Co. Can acquired a new stake in shares of Sientra in the 4th quarter worth $64,000. Finally, Vanguard Group Inc. boosted its position in shares of Sientra by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock worth $24,293,000 after purchasing an additional 14,422 shares in the last quarter. Institutional investors own 86.05% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.